CIN-103 is under clinical development by CinRx Pharma and currently in Phase I for Irritable Bowel Syndrome. According to GlobalData, Phase I drugs for Irritable Bowel Syndrome have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CIN-103’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CIN-103 is under development for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D). It is a phenol derivative. The drug candidate is a new chemical entity. It is a modified pulsatile-release formulation of phloroglucinol.
CinRx Pharma overview
CinRx Pharma is a biopharmaceutical company. It develops novel therapeutics. The company’s pipeline product portfolio include CIN-102, an antagonist for gastroparesis; CIN-103 is a novel agent for the treatment of irritable bowel syndrome of diarrheal form (IBS-D); CIN-105 for cardiovascular disease. It also operates as contract research organization (CRO). CinRx Pharma serves in the therapeutic areas of gastrointestinal disorders. The company has partnership with Medpace for carrying research operations. CinRx Pharma is headquartered in Cincinnati, Ohio, the US.
For a complete picture of CIN-103’s drug-specific PTSR and LoA scores, buy the report here.